Pieris Pharmaceuticals Inc (PIRS)

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Pieris Pharmaceuticals Inc Stock (PIRS) Company Profile

Pieris Pharmaceuticals Inc

857-246-8998

225 FRANKLIN STREET, BOSTON, MA

Prossima data di guadagno

Ultimi documenti SEC

PIRS's Discussions on Twitter

Pieris Pharmaceuticals Inc Stock (PIRS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2020-03-13	Aggiornamento	Robert W. Baird	Neutral → Outperform
2019-07-30	Downgrade	Robert W. Baird	Outperform → Neutral
2019-05-14	Iniziato	Robert W. Baird	Outperform
2018-03-19	Iniziato	Evercore ISI	Outperform
2018-03-19	Iniziato	Jefferies	Buy
2018-01-16	Reiterato	H.C. Wainwright	Buy
2017-05-30	Iniziato	Rodman & Renshaw	Buy
2016-08-05	Ripresa	ROTH Capital	Buy
2015-08-12	Iniziato	JMP Securities	Mkt Outperform
2015-07-27	Iniziato	Oppenheimer	Outperform
2015-07-22	Iniziato	ROTH Capital	Buy

Mostra tutto

Pieris Pharmaceuticals Inc Borsa (PIRS) Ultime notizie

Pieris Pharmaceuticals Inc Azioni (PIRS) Dati Finanziari

Pieris Pharmaceuticals Inc Azioni (PIRS) insider trading

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
ADAR1 Capital Management, LLC	10% Owner	Aug 09 '24	Buy	14.89	3,000	44,679	127,331

Pieris Pharmaceuticals Inc (PIRS)

Pieris Pharmaceuticals Inc Stock (PIRS) Company Profile

Pieris Pharmaceuticals Inc Stock (PIRS) Upgrades & Downgrades

Pieris Pharmaceuticals Inc Borsa (PIRS) Ultime notizie

How the (PIRS) price action is used to our Advantage - Stock Traders Daily

PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders - Business Wire

(PIRS) Investment Analysis and Advice - Stock Traders Daily

Wayne-based Palvella Therapeutics Poised to Go Public Later This Year - VISTA.Today

Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023) - Yahoo Finance

We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate - Yahoo Finance

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc.PIRS - PR Newswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders - ForexTV.com

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers of PIRS, ENV, GVP - AccessWire

Pieris Pharmaceuticals: Q2 Earnings Snapshot - San Antonio Express-News

Pieris Pharmaceuticals: Q2 Earnings Snapshot - mySA

Pieris Pharmaceuticals: Q2 Earnings Snapshot - CTPost

Pieris Pharmaceuticals: Q2 Earnings Snapshot - The Advocate

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRS - ForexTV.com

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Major Shareholder Adar1 Capital Management, Llc Purchases 3,000 Shares of Stock - Defense World

Adar1 capital management buys $92k worth of Pieris Pharmaceuticals stock - Investing.com

(PIRS) Long Term Investment Analysis - Stock Traders Daily

Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Price Passes Above 50 Day Moving Average of $10.02 - Defense World

Global Chemotherapy Induced Anemia Drug Market 2024 Analysis by Top Key Players |SBI Pharmaceuticals Co. Ltd. - The NRI News

PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders - Manchestertimes

Public Equity Report: Palvella lands on NASDAQ via Pieris merger - BioCentury

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, EMLD, ACNB, GLXZ on Behalf of Shareholders - The Malaysian Reserve

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, EMLD, ACNB, GLXZ on Behalf of Shareholders - Morningstar

General Mills, Inc. [GIS] gain 0.57% so far this year. What now? - The DBT News

PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc.PIRS - Business Wire

Viking Therapeutics stock (VKTX) could hit all time high and here’s why - BP Journal

Pieris Pharmaceuticals ($PIRS) and Palvella Therapeutics Announce Exciting Merger - BP Journal

Is today’s surge in Dermata Therapeutics (DRMA) justified ? - BP Journal

Shareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders - PR Newswire

Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings - Benzinga

PIRS Stock on the Rise: A Promising Investment - The InvestChronicle

Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga

Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results - Benzinga

Why Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today? - InvestorPlace

Ivey Business School Opens the Market to celebrate Women in Asset Management Program - The Bubble

Palvella and Pieris to merge - The Pharma Letter

Pieris Pharma stock surges on merger deal (NASDAQ:PIRS) - Seeking Alpha

Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Price Crosses Below 50 Day Moving Average of $9.25 - Defense World

Pieris Pharma Shares Double on Buyout Offer From Palvella Therapeutics - MarketWatch

Merger News Boosts Pieris (PIRS) Stock In Pre-Market Trading - Stocks Telegraph

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement - Yahoo Finance

Troutman Pepper Advises Palvella Therapeutics in Merger with Pieris Pharmaceuticals - Troutman Pepper

MEIP Stock sees a Significant Surge Amidst Strategic Evaluation - BP Journal

(PIRS) Pivots Trading Plans and Risk Controls - Stock Traders Daily

StockNews.com Initiates Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS) - American Banking and Market News

StockNews.com Initiates Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS) - Defense World

The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30% - Simply Wall St

(PIRS) Technical Pivots with Risk Controls - Stock Traders Daily

Pieris loses Servier as partner for cancer immunotherapies - pharmaphorum

Pieris Pharmaceuticals (NASDAQ:PIRS) Earns Hold Rating from Analysts at StockNews.com - Defense World

Pieris Pharma Says Servier Discontinues License Agreement - MarketWatch

Pieris Pharmaceuticals Inc Azioni (PIRS) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Pieris Pharmaceuticals Inc Azioni (PIRS) insider trading

Simile a PIRS